As the Director of Safety Pharmacology for IMAPill Inc, you’…
As the Director of Safety Pharmacology for IMAPill Inc, you’re tasked with evaluating a new drug candidate for CNS evaluation. A. In designing your experiments, describe what doses you would select and experimental structure. Please design your experiment, including group number, dosages (no numbers), and rationale for each dosing group. B. Describe 3 Nervous System Safety Assessments (2 Core, 1 Follow-Up) and how animals would be evaluated in each assessment.
Read DetailsTerfenadine was withdrawn from the market in 1997. A. Why wa…
Terfenadine was withdrawn from the market in 1997. A. Why was terfenadine withdrawn? Please include 1) a physiologic and 2) metabolic reason in your response. B. What movement (area of study) did terfenadine withdraw initiate? C. Several people a!ected by terfenadine were also found to have ingested a particular food/drink. What cellular scenario did this food/drink create?
Read DetailsSuppose the population of a species of trout in a lake is gi…
Suppose the population of a species of trout in a lake is given by a logistic model with intrinsic growth rate of k = 0.4 per year and carrying capacity of K = 10,000. In addition, suppose 500 fish are harvested from the lake each year. Which of the following differential equations describe the change in the population with respect to time?
Read Details